## Calcium Channel Blockers Treatment Selector

Charts revised February 2023. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution

| Calcium Channel Blockers | ATV/c | ATV/r | DRV/c | DRV/r | LPV/r | DOR | EFV | TDF | NVP | RPV | FTR | LEN | MVC | BIC | FTC | TDF | FTC/ TDF | DTG | EVG | EVGc | RAL | FTC/ TDF | TDF/TDF |
|--------------------------|-------|-------|-------|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|------|-----|------|------|
| Amiodipine               | ↑     | ↑     | ✔     | ❌     | ✔     | ❌  |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     | ✔    |     | ✔    |     |
| Dilazepam                | ↑     | ↑     | ❌     |     | ✔     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     |     | ✔    |     |
| Felodipine               | ↑     | ↑     | ✔     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     |     | ✔    |     |
| Lacidipine               | ↑     | ↑     | ✔     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     |     | ✔    |     |
| Lercanidipine            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     |     |     | ✔    | ✔    |
| Nicardipine              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |
| Nilnidipine              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     |     |     | ✔    |     |
| Nifedipine               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    | ✔    |
| Verapamil                | ✔     | ✔     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | ✔    |     |     | ✔    |     | ✔    |

### Interactions with CAB/RPV long acting injections

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

###Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- No a priori dosage adjustment is recommended.

###Text Legend

- Potential increased exposure of the antihypertensive
- Potential decreased exposure of the antihypertensive
- No significant effect
- One or both drugs may cause QT and/or PR prolongation.
- Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

---

**Notes**

- Coadministration may increase bictegravir concentrations; no effect on emtricitabine or tenofovir alafenamide is expected.
- Coadministration may increase bictegravir and tenofovir alafenamide concentrations; no effect on emtricitabine is expected.
- Coadministration could potentially increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration of tenofovir.
- Coadministration could potentially increase the absorption of tenofovir-DF, thereby increasing the systemic concentration of tenofovir. Monitoring of tenofovir-associated adverse reactions, including frequent renal monitoring, is recommended.